Expiration date: 11/2025

The streptococcal bacteriophage

International name:

The streptococcal bacteriophage (Bacteriophagum Staphylococcum)

Group affiliation:

Mibp-bacteriophage

Description of active substance (INN):

The streptococcal bacteriophage

Dosage form:

solution for oral administration and topical application

Pharmacological action:

It has the ability to specifically lick streptococci, including enterococci.

Indications:

Purulent-inflammatory diseases of ENT-organs, respiratory tract and lungs (sinusitis, otitis, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy), gastrointestinal tract (gastroenterocolitis, cholecystitis, dysbacteriosis), surgical infection (purulent wounds, burns, mastitis, abscess, abscess, carbuncle, hydradenitis, panaritium, abscess, bursitis, osteomyelitis), urogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis), inflammatory diseases of newborns and infants (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis), generalized septic diseases. For prevention-treatment of postoperative and newly infected wounds, as well as for the prevention of nosocomial infections according to epidemic indications.

Contraindications:

Hypersensitivity.

Method of application and doses:

Inside. Enterocolitis, diseases of internal organs, intestinal dysbiosis-3 times a day for 1 hour before meals. For 1 admission to 6 months - 5 ml, 6-12 months - 10 ml, from 1 year to 3 years - 15 ml, 3 to 8 years - 20 ml, 8 years and over - 30 ml Rectally 1 time a day (in the form of enemas) in combination with the double intake. For 1 admission to 6 months - 10 ml, 6-12 months - 20 ml, from 1 year to 3 years - 30 ml from 3 to 8 years - 40 ml, from 8 years and older in the enema of 50 ml. Locally within 7-20 days in the treatment of inflammatory diseases with localized lesions. In case of treatment of the purulent focus cavity with chemical antiseptics, rinse the cavity with sterile 0, 9% NaCl solution before using bacteriophage. Purulent wounds - in the form of irrigation, applications, bandages, the introduction of through drainage not less 1 times in day. Abscesses after opening and removal of the purulent contents, the drug is administered in an amount that is less than the volume of removed pus. In drained cavity daily 1 time per day - 20-200 ml. Osteomyelitis - 10-20 ml of the wound using turundas, drainage. Introduction to the cavity (pleural, articular, etc.). limited cavity) - to 100 ml of a bacteriophage, leaving capillary drainage, through which in a few days, the bacteriophage is introduced again. Pyo-inflammatory gynecological diseases-5-10 ml daily 1 time per day in the cavity of the vagina, uterus. Pyo-inflammatory diseases of ENT organs-2-10 ml 1-3 times a day in the middle ear cavity, nose. The bacteriophage used for rinsing, washing, backfilling, the introduction moistened with turundas (leaving them for 1 hour). Cystitis, pyelonephritis, urethritis - 20-50 ml in the bladder and 5-7 ml in the renal pelvis through the cystostomy or nephrostomy. Children up to 6 months. Sepsis, enterocolitis of newborns, including premature babies, 2-3 times a day in the form of high enemas (through a gas outlet tube or catheter). In the absence of vomiting and regurgitation, the drug is used orally, mixing with breast milk. A combination of rectal and oral administration of the drug is possible. The course of treatment - 5-15 days, with recurrent course of the disease may be repeated courses of treatment. For the prevention of sepsis and enterocolitis in intrauterine infection or the risk of nosocomial infection in newborn children bacteriophage is used in the form of enema 2 times a day for 5-7 days. Omphalitis, pyoderma, infected wounds - 2 times a day every day in the form of an application (gauze moistened with bacteriophage and put on the umbilical wound or affected area of the skin).

Special instruction:

The use of bacteriophage does not exclude the use of other drugs, including antibacterial and anti-inflammatory drugs. An important condition for effective phage therapy is a preliminary determination of focustitle of the pathogen.